SUMMARY The iron kinetic model described by Ricketts et al was used to study haemopoiesis in chronic myelofibrosis. The clearance of 59Fe-labelled transferrin from the plasma was analysed to quantify total, effective, and ineffective erythropoiesis, denoted by the terms marrow iron turnover (MIT), red cell iron turnover (RCIT), and per cent ineffective iron turnover (IIT%), respectively, in 12 cases of this disease. The patterns obtained were variable: values for MIT ranged from 24-4 to 510 umol/l blood/day; those for RCIT from 04 to 119 imol/l blood/day; and those for IIT% from 67 to 98%. One noteworthy feature was the presence in two cases of functional erythroid hypoplasia; these were characterised by severely reduced values for MIT (24-4 and 28 imol/l blood/day) and RCIT (04 and 8 Mmol/l blood/day.)
A systematic study of the erythrokinetic features of myelofibrosis may indicate that erythroid hypoplasia is a more common cause of anaemia in this disease than has been previously recognised.
Several different factors influence the severity of anaemia in myelofibrosis: among these are bone marrow failure, haematinic deficiency, blood loss, an enlarged spleen with red cell sequestration and haemolysis, plasma volume expansion, and haemoconcentration in an enlarged spleen. The erythrokinetic patterns observed in different cases and at different stages reflect these variables.
Patients and methods
Ferrokinetic measurements were carried out on 12 patients with myelofibrosis.' All had increased con- centrations of reticulin in the bone marrow; they also had enlarged spleens and blood pictures showing varying degrees of anisocytosis and poikilocytosis. Haematological data for the patients is shown in table 1. Cases 1, 2 and 3 had previously been diagnosed as having polycythaemia vera and were venesected as required, but not within 10 days before or during the ferrokinetic study. Case 4 had received busulphan during the earlier course of his disease, but no cytotoxic drugs were administered immediately before or during the ferrokinetic study. Several patients had received folic acid. Cases 7, 9, 11 and 12 were transfused as required, excluding the period 10 days Accepted for publication 31 August 1989 before or during the course of the ferrokinetic study. Case 12 had received calcitriol on previous occasions but with no apparent haematological benefit. None of the other patients received drugs during the period of study.
Transferrin bound "9Fe was prepared2 and 4 ml plasma, containing between 0-2 MBq and 0 4 MBq of label, was injected intravenously. Venous blood samples were collected at timed intervals over 10-14 days. All plasma samples were deproteinised to remove 59Fe haemoglobin before counting and curve fitting. 3 Plasma iron turnover (PIT), marrow iron turnover (MIT), red cell iron turnover (RCIT), percentage ineffective iron turnover (IIT%) and mean red cell lifespan (MRCL) were determined. Red cell volume (RCV) and plasma volume (PV) were measured by a dilution of 5'Cr labelled red cells4 and 59Fe labelled transferrin,5 respectively. Surface counting was performed over the spleen, liver, sacrum and precordium to identify sites of red cell production and destruction in 10 ofthe patients.6 Venous blood samples were stained for reticulocytes using a modification of the method of Dacie and Lewis.6 A 50:50 mixture of whole blood and 0-5% new methylene blue was prepared. After a staining period of seven minutes at room temperature a reticulocyte smear was prepared and counted using a microscope fitted with a graticule in one eyepiece.
The reference values shown in Results above. Both had normal values for PIT but showed reduced MIT and RCIT. The surface counting pattern Haematological data indicated a wide variation in also clearly differentiated these patients from thehaemoglobin concentration and reticulocyte count at others. These patients showed exclusive uptake of 59Fe presentation (table 1) . For six patients (cases [1] [2] [3] [4] [5] [6] , the by the liver with no detectable release into the haemoglobin concentration was either normal or circulation during the period of study, indicating slightly reduced. With the exception of case 3, the storage of the label rather than utilisation for eryreticulocyte count was raised. For the remaining thropoiesis. The other patients showed uptake of 59Fe patients, the haemoglobin concentration was by both spleen and sacrum, or by spleen alone, with moderately or severely reduced. Reticulocyte counts subsequent release into the circulation, suggesting use for cases 9, 11 and 12 suggested an apparent lack of of the iron for erythropoiesis rather than storage. marrow response to the anaemia. Erythrokinetic data also illustrated the heterogeneity of myelofibrosis Discussion (table 2). Ten of the patients (1-10) Were characterised by a normal or increased MIT. A normal RCIT was Our erythrokinetic studies have shown the heteroobtained for eight patients, while the remaining two geneous nature of myelofibrosis (also reflected in the (cases 9 and 10) showed a definite reduction.
clinical course) and the haematological and histoCases 11 and 12 differed considerably from the logicalfeaturesofthissyndrome.Halfofthepatients Howarth, Waters, Hyde, Geary Red cell aplasia has also been reported to complicate Philadelphia chromosome positive chronic granulocytic leukaemia'4 and also occurs in the myelodysplastic syndrome. '5 In the context of myelofibrosis, it presumably reflects an unusual phenotypic result of disordered stem cell maturation, and so far there have been no convincing reports of remission of this complication.
Myelofibrosis is a complex disorder in which the prognostic variability emphasises its heterogeneity. A systematic approach to the functional aspects of the condition will aid its characterisation and identify aspects of the syndrome which may not be readily appreciated from morphological analysis alone.
